|Javelin Pharma: Late-Stage Pipeline Targets Pain|
|Sunday, 15 March 2009 17:10|
Javelin Pharma (JAV) is focused on the late stage clinical development of three Phase 3 compounds while seeking partnerships for a non-dilutive source of funding. In mid-January, JAV established a partnership for Dyloject (injectable diclofenac) with Therabel Pharma to market the drug in Europe, where it is already approved for use.
The deal is worth up to $71M (with $12M in upfront cash and investor relation services from various entities and
firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites